Inotiv provides a fully integrated non-GLP bioanalytical drug discovery solution customized to your company’s project goals. We offer pharmacological and toxicological assessment across multiple therapeutic areas and species to ensure the right studies are performed at the right time.
Our discovery solution supports your therapeutic candidates with in vitro / in vivoDMPK, biology, PK, PD, and toxicology using high-throughput technology platforms. As your partner, you have access to unique insights that rapidly advance your discovery efforts for small molecule and biotherapeutic development.
To talk to an expert about our Nonregulated Bioanalytical Services, please click here.
We offer extensive platform suites available for small molecule bioanalysis, comprised of industry-leading instrumentation to support global studies with rapid, precise, and reproducible results. Discovery bioanalysis platforms include:
Liquid Chromatography, Tandem Mass Spectrometry
AB SCIEX™ Platform (4000, 5500, 6500, 7500)
Contemporary Method Development
Ballistic gradients, UPLC-ready columns
Tiered Stage-Appropriate Rigor for Bioanalysis
Level 1 for screening; Level 2 for non-GLP IND-enabling
High Resolution Mass Spectrometry Technology
Thermo Exploris™, LTQ Orbitrap, and Agilent 6550 Q-TOF
To learn more about our Small Molecule Nonregulated Discovery Bioanalytical service click here.
Our experienced non-GLP bioanalytical team utilize state-of-the-art molecular and cell-based platforms to rapidly develop and validate methods to support the biomarker discovery, gene therapy and biotherapeutic programs. Our capabilities include:
Protein Expression Analysis
ELISA (single and multiplex)
Transporter Assays: Solution Carrier (SLC) and ATP-Binding Cassettes (ABC)
Hepatitis B Virus (HBV) Titers
To learn more about our Biotherapeutic services for Nonregulated Discovery Bioanalytical click here.